Sulkowski, Mark - Johns Hopkins University

个人简介

Dr. Mark S. Sulkowski is a professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include hepatitis C virus infection (HCV). Dr. Sulkowski serves as the medical director of the Viral Hepatitis Center in the divisions of Infectious Diseases and Gastroenterology/Hepatology. Dr. Sulkowski received his M.D. from the Temple University School of Medicine in 1992. He completed his residency at the Duke University School of Medicine and performed a fellowship in infectious diseases in 1998 at Johns Hopkins. He is a member of numerous professional societies, including the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver and the Infectious Diseases Society of America. He is also an elected member of the American Society for Clinical Investigation (ASCI). Dr. Sulkowski is widely published, with works in Annals Internal Medicine, Nature, New England Journal of Medicine, Journal of the American Medical Association, Journal of Infectious Diseases and Hepatology. As an invited lecturer, he has presented discussions of the management of viral hepatitis at numerous major national and international medical meetings.

研究领域

An infectious disease expert, Dr. Sulkowski has been the principal investigator for numerous clinical trials related to the management of viral hepatitis, including novel agents. He is the co-investigator for adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. "Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial." Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. "Extrahepatic morbidity and mortality of chronic hepatitis C." Gastroenterology. 2015 Aug 28. pii: S0016-5085(15)01203-2. doi: 10.1053/j.gastro.2015.08.035. [Epub ahead of print] Review. Balagopal A, Barin B, Quinn J, Rogers R, Sulkowski MS, Stock PG. "Immunologic predictors of liver transplantation outcomes in HIV-HCV co-infected persons." PLoS One. 2015 Aug 27;10(8):e0135882. doi: 10.1371/journal.pone.0135882. eCollection 2015. Lawitz E, Jacobson IM, Nelson DR, Zeuzem S, Sulkowski MS, Esteban R, Brainard D, McNally J, Symonds WT, McHutchison JG, Dieterich D, Gane E. "Development of sofosbuvir for the treatment of hepatitis C virus infection." Ann N Y Acad Sci. 2015 Jul 31. doi: 10.1111/nyas.12832. [Epub ahead of print] Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.